Resistance to AC220 in FLT3-ITD+ AML is mediated by a secondary FLT3-ITD F691L mutation

被引：0
|
作者：
Albers, C. [1 ]
Leischner, H. [1 ,2 ]
Verbeek, M. [1 ]
Yu, C. [1 ]
von Bubnoff, N. [1 ]
Peschel, C. [1 ]
Duyster, J. [1 ]
机构：
[1] III Med Dept, Munich, Germany
[2] HELIOS Klinikum Berlin Buch, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [31] RGS2 is repressed by Flt3-ITD and inhibits Flt3-ITD mediated transformation of myeloid progenitor cells.
    Schwable, J
    Choudhary, C
    Tickenbrock, L
    Rudat, A
    Rehage, M
    Brandts, C
    Sargin, B
    Berdel, WE
    Muller-Tidow, C
    Serve, H
    BLOOD, 2003, 102 (11) : 220A - 220A
  • [32] Developing dual FLT3/MNK inhibitors to overcome sorafenib resistance in FLT3-ITD AML cells
    Zhao, Linxiang
    Zuo, Shuwei
    Xing, Kun
    Yue, Xiaoshuang
    Zhang, Huimin
    Zhang, Jingyi
    Waxman, Samuel
    Jing, Yongkui
    CANCER RESEARCH, 2024, 84 (06)
  • [33] Role of Enhanced Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment
    Qiu, Shaowei
    Paterson, Andrew J.
    Abraham, Ajay
    He, Jianbo
    Shah, Mansi
    Agarwal, Puneet
    Mullen, Amanda K.
    Li, Hui
    Harris, Mason W.
    Anderson, Nicholas R.
    Bhatia, Ravi
    BLOOD, 2018, 132
  • [34] FLT3-ITD Allele Frequency Is an Independent Prognostic Factor for Poor Outcome in FLT3-ITD-Positive AML Patients
    Shafik, Nevine F.
    Darwish, Amira D.
    Allam, Rasha Mahmoud
    Elsayed, Ghada M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 676 - 685
  • [35] Donor HSCs with a preexisting ASXL1-mutation led to the development of FLT3-ITD positive AML in the donor and FLT3-ITD negative AML in the recipient after unrelated transplant
    Zhongwen Liu
    Hongxing Liu
    Mingyue Shi
    Hafiz Abdul Waqas Ahmed
    Lei Huo
    Yanli Zhang
    Dai Kong
    Meiying Wen
    Fang Wang
    Mingyi Chen
    William J. Murphy
    Kai Sun
    Bone Marrow Transplantation, 2018, 53 : 499 - 502
  • [36] Donor HSCs with a preexisting ASXL1-mutation led to the development of FLT3-ITD positive AML in the donor and FLT3-ITD negative AML in the recipient after unrelated transplant
    Liu, Zhongwen
    Liu, Hongxing
    Shi, Mingyue
    Ahmed, Hafiz Abdul Waqas
    Huo, Lei
    Zhang, Yanli
    Kong, Dai
    Wen, Meiying
    Wang, Fang
    Chen, Mingyi
    Murphy, William J.
    Sun, Kai
    BONE MARROW TRANSPLANTATION, 2018, 53 (04) : 499 - 502
  • [37] The effect of FLT3 gene expression in senescence and telomere length regulation in AML cells with FLT3-ITD mutation
    Hong, Jing Siou
    Yen, Jui Hung
    Wu, Chia Ling
    Chen, Pei Yi
    CANCER SCIENCE, 2025, 116 : 256 - 256
  • [38] Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation
    Edwards, David K.
    Javidi-Sharifi, Nathalie
    Rofelty, Angela
    Rosenfeld, Claire
    Roth-Carter, Riley
    Tardi, Paul
    Mayer, Lawrence
    Tyner, Jeffrey W.
    BLOOD, 2016, 128 (22)
  • [39] Molecular mechanism underlying Survivin expression in FLT3-ITD+ AML cells
    Namekawa, Tomoya
    Nishi, Ryotaro
    Hori, Toshiyuki
    CANCER SCIENCE, 2018, 109 : 397 - 397
  • [40] Influence of IDH on FLT3-ITD status in newly diagnosed AML
    Boddu, P.
    Takahashi, K.
    Pemmaraju, N.
    Daver, N.
    Benton, C. B.
    Pierce, S.
    Konopleva, M.
    Ravandi, F.
    Cortes, J.
    Kantarjian, H.
    DiNardo, C. D.
    LEUKEMIA, 2017, 31 (11) : 2526 - 2529
12345